EP1675594A2 - Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases - Google Patents
Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseasesInfo
- Publication number
- EP1675594A2 EP1675594A2 EP04790487A EP04790487A EP1675594A2 EP 1675594 A2 EP1675594 A2 EP 1675594A2 EP 04790487 A EP04790487 A EP 04790487A EP 04790487 A EP04790487 A EP 04790487A EP 1675594 A2 EP1675594 A2 EP 1675594A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- unsubstituted
- compounds
- substituted
- tautomers
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C251/80—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/61—Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- New dipeptidyl peptidase IV inhibitors for the functional influencing of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
- Dipeptidyl peptidase IV (DP1N, CD26, EC 3.4.14.5) is a ubiquitous serine protease that catalyzes the hydrolysis of peptides specifically behind proline or alanine in the second position of the ⁇ -terminus.
- the DPIV gene family with enzymatic activity includes a. DP 8, DP 9 and FAP / Seprase (T. Chn et al .: Adv. Exp. Med. Biol. 524, 79, 2003).
- a similar substrate specificity as DPIV has attractin (mahogany protein) (J. S. Duke-Cohan et al: J. Immunol. 156, 1714, 1996).
- the enzyme is also inhibited by DPIV inhibitors.
- dipeptidyl peptidase IV and the other peptidases Different inhibitors are known for the dipeptidyl peptidase IV and the other peptidases (Review in DM Evans: Drugs 5, 577, 002).
- the isolated inhibition of dipeptidyl peptidase IV and analog peptidases but in particular the combined inhibition of dipeptidyl peptidase IV and alanyl aminopeptidases (EC 3.4.11.2 and EC 3.4.11.14) leads to strong inhibition of DNA synthesis and thus cell proliferation and also to immune cells Change in cytokine production, in particular for induction of the immunoregulatory TGF- ⁇ 1 (international patent application WO 01/89569 Dl, international patent application WO 02/053170 A3).
- Alanyl aminopeptidase inhibitors induce a strong induction of TGF-ß1 on regulatory T cells (international patent application PCT / EP 03/07199).
- a reduction or delay in acute and chronic cerebral damage processes has been demonstrated in the neural system by inhibiting dipeptidyl peptidase TV or analogous enzymes, but especially by combined inhibition of DPIV or analogous enzymes and alanyl aminopeptidases or analogous enzymes (international patent application WO 02 /
- the object of the present invention was to find further effective inhibitors of dipeptidyl peptidase IN and analogous enzymes.
- low molecular weight, easily accessible compounds should be found which are effective, i.e. H. allow effective inhibition of Dipeptidylpeptidase TV and analog enzymes.
- the invention relates to new substances which specifically inhibit Gly-Pro-p-itroanilide-cleaving peptidases.
- the invention also relates to new substances which, as such or as starting materials for further substances and in combination with inhibitors of alanyl aminopeptidase or analogous enzymes for the prophylaxis and therapy of diseases with an excessive immune response (autoimmune diseases, allergies and transplant rejections, sepsis), are other chronic inflammatory diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis) and tumor diseases can be used.
- autoimmune diseases allergies and transplant rejections, sepsis
- sepsis are other chronic inflammatory diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis) and tumor diseases can be used.
- the present invention relates to compounds of the general formulas Dl to D14 according to claims 1, 3, 5, 1, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27 as well as tautomers and stereoisomers of the compounds mentioned general formulas Dl to D14 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for use in medicine.
- the invention relates to special, preferred compounds of the special formulas Dl.001 to D14.007, which fall under the general formulas Dl to D14 above, which are exemplary but not restrictive in claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28 are listed in the form of tables, as well as tautomers and stereoisomers of the compounds mentioned of the general formulas Dl.001 to D14.007 and pharmaceutically acceptable salts, salt derivatives, tautomers and Stereoisomers thereof, for use in medicine.
- the invention further relates to pharmaceutical compositions which comprise at least one compound of one of the general formulas Dl to D 14, optionally in combination with carriers or adjuvants which are customary per se.
- the invention further relates to cosmetic compositions which comprise at least one compound of one of the general formulas D1 to D 14, optionally in combination with carriers or adjuvants which are customary per se.
- the invention further relates to the use of at least one compound of the general formulas Dl to D 14 or at least one of the aforementioned pharmaceutical or cosmetic compositions for inhibiting the activity of the dipeptidyl peptidase IN or analogous enzymes, either alone or in combination with inhibitors of alanyl aminopetidases or analog enzymes.
- the invention further relates to the use of at least one compound of one of the general formulas Dl to D 14 or at least one of the aforementioned pharmaceutical or cosmetic compositions for topically influencing the activity of dipeptidyl peptidase IV or analogous enzymes, either alone or in combination with inhibitors of alanyl aminopeptidases or analog enzymes.
- the invention further relates to the use of at least one compound of one of the general formulas Dl to D14 or at least one of the aforementioned pharmaceutical or, if appropriate, also cosmetic compositions for the prophylaxis and therapy of a whole number of diseases, which are claimed in claims 33 to 45 by way of example.
- the compounds of the general formulas Dl to Dl in particular the particularly preferred individual compounds Dl.001 to D14.007 listed in Tables 1 to 14, as such or as starting materials for further substances and in combination with inhibitors of alanyl aminopetidases and analogous enzymes for the therapy of diseases with excessive immune response (autoimmune diseases, allergies and transplant rejections), of other chronic inflammatory diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis), tumor diseases and special virus infections (including SARS) can be used.
- diseases with excessive immune response autoimmune diseases, allergies and transplant rejections
- other chronic inflammatory diseases e.g., neuronal diseases and cerebral damage
- skin diseases including acne and psoriasis
- tumor diseases and special virus infections including SARS
- the invention further relates to the use of at least one compound of one of the general formulas Dl to D 14 or at least one of the aforementioned pharmaceutical or cosmetic compositions for the manufacture of a medicament for inhibiting the activity of the dipeptidyl peptidase TV or analogous enzymes, either alone or in combination with inhibitors of Alanyl aminopeptidases or analog enzymes.
- the invention further relates to the use of at least one compound of one of the general formulas Dl to D 14 or at least one of the aforementioned pharmaceutical or cosmetic compositions for producing a medicament for topically influencing the activity of the dipeptidyl peptidase IN or analogous enzymes, either alone or in combination with inhibitors of alanyl aminopeptidases or analogous enzymes.
- the invention further relates to the use of at least one compound of one of the general formulas Dl to D 14 or at least one of the aforementioned pharmaceutical or, if appropriate, also cosmetic compositions for the production of a medicament for the prophylaxis and therapy of a whole number of diseases, which are exemplary in claims 48 to 60 are claimed.
- the compounds of the general formulas Dl to Dl can be used as such or as starting materials for further substances and in combination with inhibitors of alanyl Aminopeptidases and analogous enzymes for the manufacture of a medicament for the therapy of diseases with an excessive immune response (autoimmune diseases, allergies and graft rejections), of other chronic inflammatory diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis), tumor diseases and special viral infections (among others SARS) can be used.
- the invention further relates to a method for inhibiting the activity of dipeptidyl peptidase IV or analogous enzymes alone or in combination with inhibitors of alanyl aminopeptidase and analogous enzymes by administration of at least one compound of the general formulas Dl to D14 or at least one of the above pharmaceutical or cosmetic compositions in an amount required to inhibit enzyme activity.
- the invention further relates to a method for topically influencing the activity of dipeptidyl peptidase IV or analogous enzymes alone or in combination with inhibitors of alanyl aminopeptidases and analogous enzymes by administration of at least one compound of the general formulas Dl to D 14 or at least one of the above pharmaceutical or cosmetic Compositions in an amount necessary to inhibit enzyme activity.
- the invention further relates to a method for the prophylaxis and / or therapy of one of the diseases or conditions claimed in claims 63 to 76 while inhibiting the activity of dipeptidyl peptidase TV or analogous enzymes alone or in combination with inhibitors of alanyl aminopeptidase and analogous enzymes by administration at least one compound of the general formulas Dl to D14 or at least one of the above pharmaceutical or cosmetic compositions in an amount required for prophylaxis or therapy.
- analogous enzymes refers to enzymes which have an enzyme activity analogous to dipeptidylpeptidase IN, such as, for example, for the DP8, DP9, for FAP / Seprase or for the attractin.
- DP8 dipeptidylpeptidase IN
- FAP FAP / Seprase
- attractin the term is also explained in this sense in the publication cited above "AJ Barrett et al .: Handbook of Proteolytic Enzymes, Academic Press 1998".
- radicals are in the general formulas Dl to Dl 4, as they result from claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27 in general form Rn, that is to say the radicals Rl, R2, R3, R4, R5, R6, R7, R8, R9 and RIO, in each case independently of one another, for a radical which is selected from the group consisting of hydrogen, unsubstituted or substituted, straight or branched C ⁇ - C 1 - alkyl, C 2 - to C 12 alkenyl and C 2 - to C 12 alkynyl, hydroxy, thiol, C ⁇ - C 12 alkoxy, Ci to C alkylthio 1 , Unsubstituted or substituted, uncondensed or fused, optionally containing one or more heteroatoms from the group ⁇ , O, P and S aryl and cycloalkyl, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubsti
- radicals Rn in embodiments according to the invention when they represent unsubstituted straight-chain or branched alkyl groups having 1 to 12 carbon atoms, in preferred embodiments methyl, ethyl, n-propyl, i-propyl, n-butyl, i - Butyl, sec-butyl, tert-butyl, n-pentyl, i-pentyl, sec-pentyl, tert-pentyl, n-hexyl, i-hexyl, 3-methylpentyl, 2-ethylbutyl, 2,2-dimethylbutyl and for the residues heptyl, octyl, ⁇ onyl, decyl, undecyl and dodecyl all straight-chain and branched isomers.
- alkyl groups with 1 to 6 carbon atoms are particularly preferred.
- methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and tert-butyl are more preferred.
- the radicals Rn can also stand for straight-chain and branched alkenyl groups with several double bonds.
- Preferred radicals from this group are the butadienyl group and the isoprenyl group. According to the invention, particularly preferred from the aforementioned group are alkenyl groups with 2 to 6 carbon atoms; of these, vinyl, allyl, 1-butenyl and 2-butenyl are more preferred.
- the radicals Rn when they represent unsubstituted straight-chain or branched alkynyl groups having 2 to 12 carbon atoms, in preferred embodiments are ethynyl, propynyl, 1-butynyl, 2-butynyl, and for the radicals pentynyl, hexynyl, Heptinyl, octynyl, nonynyl, decynyl, undecynyl and dodecynyl all straight-chain and branched residues conceivable with regard to the position of the C ⁇ C triple bond.
- particularly preferred from the aforementioned group are alkynyl groups with 2 to 6 C atoms; of these, ethynyl, propynyl, 1-butynyl and 2-butynyl are more preferred.
- both straight-chain and branched alkyl, alkenyl or alkynyl radicals can be substituted in a further embodiment.
- the substituents can be located at any position on the basic structure formed from carbon atoms and can be selected from the group consisting of halogen atoms such as fluorine, chlorine, bromine and iodine, alkyl groups with 1 to 6 C atoms, alkoxy groups with 1 to 6 C atoms in the alkyl radical and unsubstituted or with one or two alkyl radicals each independently substituted by 1 to 6 carbon atoms.
- the radicals Rn represent in the general formulas Dl to D14 - to C 12 -alkoxy radicals or to C 12 alkylthio residues.
- the above-mentioned definitions of the straight-chain and branched alkyl radicals also apply to the Ci to C 12 alkyl groups of these alkoxy or alkylthio radicals.
- Straight-chain C 1 -C 6 -alkoxy radicals and straight-chain C 1 -C 6 -alkylthio radicals, and the radicals methoxy, ethoxy, n-propoxy, methylthio, ethylthio and n-propylthio are particularly preferred.
- the radicals Rn of the general formulas Dl to D 14 can also represent unsubstituted or substituted cycloalkyl radicals. According to the invention, these can preferably contain three to eight atoms in the ring and can either consist exclusively of carbon atoms or contain one or more heteroatoms.
- cyclopentyl particularly preferred among the purely carbocyclic rings are cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptenyl, cycloheptadienyl and cycloheptatrienyl;
- cycloalkyl radicals containing heteroatoms in further embodiments of the invention are the radicals tetrahydrofuranyl, pyrrolidinyl, pyrazolidinyl, hnidazolidinyl, piperidinyl, piperazinyl and morpholinyl.
- Possible substituents on these carbocyclic or heterocyclic cycloalkyl radicals can be selected from the above group of substituents for linear alkyl groups.
- the radicals Rn on the compounds of the general formulas Dl to D14 can be uncondensed or condensed aryl radicals optionally containing one or more heteroatoms from the group consisting of N, O, P and S.
- the aryl radicals can consist of one or more rings, preferably two rings in the case of several rings; a ring can further preferably have five, six or seven ring members.
- benzo-condensed rings are particularly preferred, i. H. Ring systems in which at least one of the rings is an aromatic six-membered ring.
- the aryl radicals consisting purely of carbon atoms are particularly preferably selected from phenyl, cyclopentadienyl, cycloheptatrienyl and naphthyl;
- Aryl radicals containing particularly preferred heteroatoms are selected, for example, from indolyl, coumaronyl, thionaphthenyl, quinolinyl (benzopyridyl), quinazolinyl (benzopyrimidinyl) and quinoxylinyl (benzopyrazinyl).
- Aryl residues consisting of one ring as well as several rings, both containing only carbon atoms and containing heteroatoms, can be invented. be substituted according to the invention in a further embodiment.
- the substituents can be located at any position in the ring system, both on the carbon atoms and on the heteroatoms, and can be selected, for example, from the group consisting of halogen atoms such as fluorine, chlorine, bromine and iodine, alkyl groups with 1 to 6 carbon atoms, Alkoxy groups with 1 to 6 carbon atoms in the alkyl radical and unsubstituted or with one or two alkyl radicals each with independently substituted 1 to 6 carbon atoms.
- the radicals Rn can also, according to the invention, also for unsubstituted amino radicals (-NH) or unsubstituted imino radicals (-NH-) or for substituted amino radicals (-NHRm or -NRlRm) or substituted imino radicals (-NRm) are available.
- substituents Rl and Rm have the meanings defined in detail above for the radicals Rn and can be the same and different.
- the substituents Rm of substituted carbonyl radicals or substituted thiocarbonyl radicals have the meanings defined above in detail for the possible substituents of the radicals Rn.
- Rn it is equally possible for the radicals Rn to be connected to the respective basic structures of the general formulas D1 to D14 via the hetero atom or one of their heteroatoms.
- the radicals Y each independently represent one of the radicals O, S or NRn, for example NR3 or NR4 or NR5, which are bonded to a carbon atom via a double bond
- the radicals Rn (for example R3 or R4 or R5) can have the meanings given above for Rn, including the meaning hydrogen.
- Y particularly preferably represents O bonded to a C atom via a double bond.
- X, XI, X2 and Z represent radicals which each have a CX single bond (or C-Xl single bond or C-X2 Single bond) or a CZ single bond are bonded to two different carbon atoms.
- radicals X and Z in the general formulas in which they occur each independently represent one of the radicals>NH,> NRn (e.g.> NR5 or> NR10), each bonded to a single bond to two different carbon atoms, - O-, -S-, -CH 2 -, -CHRn- or -CRn 2 -, in which the radicals Rn have the meaning given above, or stand for one of the radicals bonded via three single bonds to three different carbon atoms, > CH- or> CRn- (e.g.> CR8- or> CR9-), wherein Rn (e.g. R8, R9) have the meanings given above.
- NRn e.g.> NR5 or> NR10
- R1 and R12 represent heterocyclic systems with three to eight ring members which can be connected directly via the heteroatoms, carbon atoms or a hetero or carbon atom, and the partial rings denoted by R1 and R2 can be substituted or may be substituted, condensed or uncondensed and may contain zero to three double bonds and further heteroatoms and groups containing heteroatoms.
- Z represents P or S.
- X and Z independently of one another represent radicals from the group consisting of hydroxy, thiol, Ci to C 12 alkoxy, d to C 12 alkyltio, unsubstituted or substituted, uncondensed or condensed based, optionally containing one or more heteroatoms from the group N, O, P and S aryl and cycloalkyl and amino (NH 2 , NHR1, NR1R2), in which all of the above meanings of X and Z are those for alkoxy, alkylthio, aryl, cycloalkyl and Amino correspond to those defined above for the radicals Rn of the general formulas Dl to D14 in detail.
- the compounds corresponding to the general formulas Dl to D 14 in general and the special compounds DlOOl to Dl 4.007 mentioned in Tables 1 to 14 are claimed in preferred embodiments of the invention for use in medicine.
- the term “for use in medicine” is understood here in its broadest meaning as in the claims and relates to all conceivable fields of application in which the compounds of the general formulas Dl to D14 defined by the present invention and, in preferred embodiments, the compounds Dl.OOl to D14.007, as they are specifically listed in Table 1 to 14, can develop effectiveness in connection with medically relevant conditions of the mammalian body, in particular the human body.
- the compounds of the general formulas Dl to D 14 are used in general and the preferred compounds DlOOl to D14.007 according to Tables 1 to 14 are used either in the form of the use of a single compound or in the form of the Use of several compounds of the general formulas Dl to D14 (in particular the preferred compounds DlOOl to D14.007 according to Tables 1 to 14) instead.
- the use of one or more of the compounds of the general formulas Dl to D14 preferably one or more compounds from the group selected from the group Compounds Dl.OOl to D14.007 according to Table 1 to 14, in combination with other active ingredients, for example with one or more compounds, the effectiveness in the inhibition of dipeptidyl peptidase IV or of analogous enzymes (i.e. enzymes with the same substrate specificity) and / or effectiveness in the inhibition of other enzymes, for example alanyl aminopeptidase (APN) or of analogous enzymes (ie enzymes with the same substrate specificity).
- APN alanyl aminopeptidase
- analogous enzymes ie enzymes with the same substrate specificity
- inhibitors which act as inhibitors of dipeptidyl peptidase IN can include, for example: Xaa-Pro dipeptides, corresponding derivatives, preferably di-petidophosphonic acid diaryl esters, dipeptide boronic acids (e.g.
- Xaa-Xaa- (Trp) -Pro- ( Xaa) n-peptides (n 0 to 10), corresponding derivatives and their salts or amino acid (Xaa) amides, corresponding derivatives and their salts, where Xaa is an ⁇ -amino acid / imino acid or an ⁇ -amino acid derivative / imino acid derivative, preferably ⁇ ⁇ - 4-nitrobenzyloxycarbonyl-L-lysine, L-proline, L-tryptophan, L-isoleucine, L-valine and cyclic amines, for example pyrrolidine, piperidine, thiazolidine and their derivatives, act as the amide structure.
- TSL tryptophan-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives
- (2S, 2S ') , 2S ") 2- [2 '- [2" -amino-3 "- (indol-3'" - yl) -l "-oxoprolyl] -, 2 ', 3', 4'-tetrahydro-6 '8'-dihydroxy-7-methoxyisoquinol-3-yl-carbonylamino] -4-hydromethyl-5-hydropentanoic acid (TMC-2A)
- TSC-2A can be used, for example, advantageously together with the compounds of the general formulas Dl to D14 usable Inhibitor of DP IV
- a further embodiment of the invention relates to pharmaceutical preparations which contain at least one, optionally also two or even more, compound (s) of the general formulas Dl to D14, particularly preferably selected from the compounds DlOOl to D14.007 according to Tables 1 to 14 , include.
- Such pharmaceutical preparations comprise one or more of the compounds mentioned in each case in such an amount as is necessary for the development of a pharmaceutical effect.
- the person skilled in the art can determine such quantities easily and without inventive step using a few routine tests; they are generally in the range from 0.01 to 1000 mg of each of the compounds of the general formulas Dl to Dl 4, particularly preferably the compounds DlOOl to D14.007 according to Tables 1 to 14, per administration unit, even more preferably in the range from 0.1 to 100 mg of each of the compounds mentioned per dosage unit.
- the person skilled in the art can easily determine quantities tailored to the respective individual mammalian organism or human organism and, if appropriate, also provide that a sufficient concentration of the compound (s) to be used is achieved by administering divided or several dosage forms.
- a further embodiment of the invention relates to cosmetic preparations which contain at least one, optionally also two or even more, compound (s) of the general formulas Dl to D14, particularly preferably selected from the compounds DlOOl to Dl 4.007 according to Tables 1 to 14, include.
- Such cosmetic preparations comprise one or more of the compounds mentioned in each case in such an amount as is necessary for the development of a desired, for example cosmetic, effect.
- the person skilled in the art can determine such quantities easily and without inventive step using a few routine tests; they are generally in the range from 0.01 to 1000 mg of each of the compounds of the general formulas Dl to D14, particularly preferably the compounds DlOOl to D14.007 according to Tables 1 to 14, per administration unit, even more preferably in the range from 0 , 1 to 100 mg of each of the compounds mentioned per dosage unit.
- the person skilled in the art can also easily determine coordinated amounts and, if appropriate, also provide that a sufficient concentration of the compounds to be used is achieved by administering divided or several dosage forms.
- the one or more compounds according to the present invention or pharmaceutical or cosmetic preparations containing them are administered simultaneously with known carriers and / or auxiliaries (adjuvants).
- carriers and auxiliary substances are known to the person skilled in the art as such and also with regard to their function and mode of use and therefore do not require any detailed explanation at this point.
- the invention also includes pharmaceutical preparations which comprise: one or more of the inhibitors of DP TV or the inhibitors of enzymes with DP 1N-analogous enzyme activity or / and the inhibitors of APN or the inhibitors of enzymes with APN-analogous enzyme activity according to the prior art, together with one or more compound (s) of the general formulas Dl to Dl 4, particularly preferably together with one or more of the compounds selected from the compounds Dl.OOl to D14.007 in Tables 1 to 14 are, in spatially separate formulation in combination with known carriers, auxiliaries and / or additives for simultaneous or immediately sequential administration with the aim of a common effect.
- Auxiliaries and / or additives comprise, on the one hand, as a topical application in the form of, for example, creams, ointments, pastes, gels, solutions, sprays, liposomes and nanosomes, shaking mixtures, "pegylated” formulations, and degradable (ie degradable under physiological conditions) depot -Matrices, HydrocoUoid bandages, plasters, microsponges, prepolyomers and similar new carrier substrates, jet injection or other dermatological bases / vehicles including instillative application, and on the other hand as a systemic application for oral len, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, intrethecal use in suitable formulations or in suitable gal
- the compounds of the general formulas Dl to D 14 in general and preferably the compounds DlOOl to D14.007 according to Tables 1 to 14 individually or in combination, or else pharmaceutical or cosmetic compositions which comprise one or more of the compounds mentioned, used to inhibit the activity of Dipeptidylpeptidase TV or analog enzymes alone or in combination with inhibitors of alanyl aminopeptidases and inhibitors of analog enzymes.
- the compounds of the general formulas Dl to D14 in general and preferably the compounds DlOOl to D14.007 according to Tables 1 to 14 individually or in combination, or else pharmaceutical or cosmetic compositions which comprise one or more of the Compounds mentioned include, for topical influencing the activity of the dipeptidyl peptidase IN or analog enzymes used alone or in combination with inhibitors of alanyl aminopeptidases and inhibitors of analog enzymes.
- the compounds of the general formulas Dl to D14 are used in general and preferably the compounds DlOOl to Dl 4.007 according to Tables 1 to 14 individually or in combination, or else pharmaceutical or cosmetic compositions which comprise a or include more of the compounds mentioned, for the prophylaxis and therapy of diseases such as, for example, multiple sclerosis, Crohn's disease, ulcerative colitis, and other autoimmune diseases and inflammatory diseases, bronchial asthma and other allergic diseases, skin and mucous membrane diseases, for example psoriasis, acne and dermatological diseases with hyperproliferation and altered differentiation states of fibroblasts, benign fibrosing and sclerosing skin diseases and malignant fibroblastic hyperproliferation states, acute neuronal diseases such as ischemia-related severe cerebral damage after an ischemic or hemorrhagic stroke, skull / brain trauma, cardiac arrest, heart attack or as a result of cardiac surgery, chronic neuronal diseases, for example Alzheimer's disease, Pick's disease, progressive
- the compounds of the general formulas Dl to D 14 are used in general and preferably the compounds DlOOl to Dl 4.007 according to Tables 1 to 14 individually or in combination, or else the pharmaceutical or cosmetic compositions comprise one or more of the compounds mentioned, for the prophylaxis and therapy of the rejection of transplanted tissues and cells.
- the use of one or more of the abovementioned compounds or a pharmaceutical composition which contains one or more of the abovementioned compounds in conventional kidney or stem cell transplantations can be mentioned.
- the compounds of the general formulas Dl to D14 are used in general and preferably the compounds DlOOl to D14.007 according to Tables 1 to 14 individually or in combination, or else the pharmaceutical or cosmetic compositions comprise one or more of the compounds mentioned, for the prophylaxis and therapy of the rejection or inflammatory reactions on or by medical objects implanted in an organism (“medical devices”).
- the compounds of the general formulas Dl to D14 are used in general and preferably the compounds DlOOl to D14.007 according to Tables 1 to 14 individually or in Combination, or else the pharmaceutical or cosmetic compositions, which comprise one or more of the compounds mentioned, in such a way that the compounds or compositions are applied in the form of a coating or wetting to the article or articles or at least one the compounds or compositions are materially admixed with the material of the object (s). In this case too, it is of course possible to administer at least one of the compounds or compositions locally or systemically, if appropriate in chronological order or in parallel.
- the invention also relates to a method for inhibiting the activity of the dipeptidyl peptidase IN or analogous enzymes alone or in combination with inhibitors of alanyl aminopeptidases and analogous enzymes by administration of at least one compound or pharmaceutical or cosmetic composition according to the detailed description above in one for the inhibition the amount of enzyme activity required.
- the amounts of one of the compounds of the general formulas Dl to D14 in general or of the compounds DlOOl to D14.007 according to Tables 1 to 14 are, as indicated above, in the range from 0.01 to 1000 mg of a compound per administration unit, preferably in the range of 0.1 to 100 mg per administration unit.
- the invention also relates to a method for topically influencing the activity of the dipeptidyl peptidase IN or analogous enzymes alone or in combination with inhibitors of alanyl aminopeptidase or analogous enzymes by administration of at least one compound or pharmaceutical or cosmetic composition according to the detailed description above in one for the Affecting the amount of enzyme activity required. In these cases, too, the amounts of the compound (s) are in the range given above.
- the invention also relates to a method for the prophylaxis and therapy of a large number of diseases, for example diseases with an excessive immune response (autoimmune diseases, allergies and transplant rejections), other chronic inflammatory diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis), Tumor diseases and special viral infections (including SARS) and in particular the diseases mentioned in detail above, by administration of at least one compound or pharmaceutical or cosmetic composition according to the detailed description above in an amount required for the prophylaxis or therapy of the respective disease.
- the amounts of the compound (s) range from 0.01 to 1000 mg of a compound per administration unit, preferably in the range from 0.1 to 100 mg per administration unit.
- Tables 1 to 14 summarize new inhibitors for which it has been possible for the applicant to show that these substances are able to inhibit dipeptidyl peptidase IN and enzymes having an analogous effect in their enzymatic activity.
- the measured inhibition characteristics are given as IC-50 or ID-50 values (DD-50 values marked with "*") for both enzymes.
- the enzymatic activity was determined using the fluorogenic substrates (Ala-Pro) 2 -Rhodamine 110 ,
- the disease scores are defined by different degrees of paralysis. Healthy animals have a disease score of 0.
- Actinonin was used as the alanyl aminopeptidase inhibitor and Lys [Z (NO2)] pyrrolidide as the dipeptidyl peptidase IV inhibitor. The treatment was carried out over 46 days after immunization. The results are shown in Figure 1. The curves clearly show a particularly strong and lasting therapeutic effect after combined inhibition of both peptidases.
- Example 3 The curves clearly show a particularly strong and lasting therapeutic effect after combined inhibition of both peptidases.
- Inflammation predominantly affecting the colon was induced by administration of 3% sodium dextran sulfate in drinking water in 8-week-old female Balb / c mice. After 3 days, all animals show clear symptoms typical of the disease.
- the peptidase inhibitors or the phosphate-buffered saline as placebo were administered intraperitoneally from day 5 on for three consecutive days. The severity is determined using a recognized rating system.
- Sensitization to the bronchial-inducing antigen ovalbumin was carried out on female Balb / c mice by intraperitoneal administration of 10 ⁇ g ovalbumin each on days 0, 14 and 21. On days 27/28, the animals were boosted by inhalation with ovalbumin. After intraperitoneal application of the peptidase inhibitors on days 28-35, an intranasal ovalbumin challenge followed on day 35 and a check of the early allergic reaction via lung function. The mean expiratory flow EF50, the tidal volume, the respiratory rate and the minute volume as well as the number of eosinophilic granulocytes in the bronchoalveolar lavage were measured. 8-10 animals were used for each experimental group.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10348022A DE10348022A1 (en) | 2003-10-15 | 2003-10-15 | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
PCT/EP2004/011645 WO2005037779A2 (en) | 2003-10-15 | 2004-10-15 | Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1675594A2 true EP1675594A2 (en) | 2006-07-05 |
Family
ID=34441989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04790487A Withdrawn EP1675594A2 (en) | 2003-10-15 | 2004-10-15 | Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070037785A1 (en) |
EP (1) | EP1675594A2 (en) |
JP (1) | JP2008500270A (en) |
CN (1) | CN1889960A (en) |
AU (1) | AU2004281959B9 (en) |
CA (1) | CA2542807A1 (en) |
DE (1) | DE10348022A1 (en) |
WO (1) | WO2005037779A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680150B2 (en) | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1606285A4 (en) * | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | Novel ido inhibitors and methods of use |
FR2865732B1 (en) * | 2004-01-30 | 2007-10-12 | Clinigenetics | HYDRAZID-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES |
MX2007003381A (en) | 2004-09-22 | 2007-04-27 | Lundbeck & Co As H | 2-acylaminothiazole derivatives. |
DOP2006000008A (en) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
WO2006110516A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
TW200720264A (en) * | 2005-04-25 | 2007-06-01 | Lundbeck & Co As H | Pro-drugs of n-thiazol-2-yl-benzamide derivatives |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
US8034953B2 (en) * | 2005-05-10 | 2011-10-11 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2006132583A1 (en) * | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
DE102005027169A1 (en) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | tetrahydroquinoline |
CN1891704A (en) * | 2005-07-08 | 2007-01-10 | 中国科学院上海药物研究所 | Dipetidase tetrainhibitor, and its preparing method and use |
JP2009515839A (en) * | 2005-11-15 | 2009-04-16 | メルク フロスト カナダ リミテツド | Azacyclohexane derivatives as stearoyl-CoA delta-9 desaturase inhibitors |
TWI382974B (en) * | 2005-12-20 | 2013-01-21 | Incyte Corp | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
AU2006326815A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
WO2007073555A1 (en) * | 2005-12-20 | 2007-06-28 | Gilead Colorado, Inc. | Use of 4, 7-dihydrothieno [2, 3-b] pyridine compounds in the treatment of cardiovascular diseases |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
AU2006327069A1 (en) * | 2005-12-23 | 2007-06-28 | Novartis Ag | Condensed heterocyclic compounds useful as DPP-IV inhibitors |
EP2004649B1 (en) * | 2006-03-24 | 2012-07-04 | The Feinstein Institute for Medical Research | Phenolic hydrazone macrophage migration inhibitory factor inhibitors |
PE20071221A1 (en) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
WO2007148185A2 (en) * | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
JP5319532B2 (en) * | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | N-hydroxyamidino heterocycle as a modulator of indoleamine 2,3-dioxygenase |
US20080081913A1 (en) * | 2006-09-29 | 2008-04-03 | General Electric Company | Benzoxazole and benzothiazole compounds and methods therefor |
US20080081210A1 (en) * | 2006-09-29 | 2008-04-03 | General Electric Company | Authenticatable articles and methods therefor |
EP2076134A4 (en) * | 2006-10-10 | 2020-07-29 | President and Fellows of Harvard College | Compounds, screens, and methods of treatment |
US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
WO2008064342A2 (en) * | 2006-11-21 | 2008-05-29 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
EA200901167A1 (en) * | 2007-03-06 | 2010-04-30 | Новартис Аг | Bicyclic organic compounds suitable for the treatment of inflammatory and allergic states |
US8283351B2 (en) | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
JP2010540527A (en) | 2007-09-25 | 2010-12-24 | アボット・ラボラトリーズ | Octahydropentalene compounds as chemokine receptor antagonists |
TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
EP2278879B1 (en) | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
WO2009155362A1 (en) * | 2008-06-19 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Small molecule hematopoietic growth factor mimetic compounds and their uses |
PT2315756E (en) | 2008-07-08 | 2014-12-16 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
AR077642A1 (en) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME |
EP2480531B1 (en) * | 2009-09-21 | 2014-11-05 | ChemoCentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012003476A2 (en) * | 2010-07-02 | 2012-01-05 | Ventana Medical Systems, Inc. | Hapten conjugates for target detection |
EA201390421A1 (en) | 2010-09-22 | 2013-09-30 | Арена Фармасьютикалз, Инк. | GPR119 RECEPTOR MODULATORS AND TREATMENT OF RELATED DISORDERS |
EP2505589A1 (en) * | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
ES2724531T3 (en) | 2011-05-12 | 2019-09-11 | Proteostasis Therapeutics Inc | Proteostasis Regulators |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CN102260268B (en) * | 2011-06-19 | 2013-04-03 | 漆又毛 | Benzylthio acetamido acetylpyrazine triazole derivative as well as preparation thereof and application thereof |
EP2753176A4 (en) * | 2011-09-06 | 2015-10-21 | New York Blood Ct Inc | Hiv inhibitors |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013076275A1 (en) * | 2011-11-23 | 2013-05-30 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv.Trinity Of Queen Elizabeth Near Dublin | Androgen receptor ligands |
SI2800565T1 (en) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Carbamate compounds and methods of making and using same |
WO2013149376A1 (en) | 2012-04-02 | 2013-10-10 | Abbott Laboratories | Chemokine receptor antagonists |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US20150174034A1 (en) | 2013-03-13 | 2015-06-25 | Avon Products, Inc. | Tyrosinase inhibitors |
WO2014164195A1 (en) | 2013-03-13 | 2014-10-09 | Avon Products, Inc | Tyrosinase inhibitors |
PT3066085T (en) | 2013-11-08 | 2020-07-16 | Incyte Holdings Corp | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
JP6595983B2 (en) * | 2014-04-04 | 2019-10-23 | 株式会社Adeka | Oxime ester compound and photopolymerization initiator containing the compound |
US9383644B2 (en) | 2014-09-18 | 2016-07-05 | Heraeus Precious Metals North America Daychem LLC | Sulfonic acid derivative compounds as photoacid generators in resist applications |
WO2016044808A1 (en) | 2014-09-19 | 2016-03-24 | New York Blood Center, Inc. | Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv |
CN105985769B (en) * | 2015-01-28 | 2018-02-02 | 苏州罗兰生物科技有限公司 | A kind of preparation and application of benzenethiol fluorescence probe |
KR20220070057A (en) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US9477150B2 (en) | 2015-03-13 | 2016-10-25 | Heraeus Precious Metals North America Daychem LLC | Sulfonic acid derivative compounds as photoacid generators in resist applications |
EP3271352B1 (en) | 2015-03-18 | 2021-05-12 | H. Lundbeck A/S | Piperazine carbamates and methods of making and using same |
BR112017024253A2 (en) | 2015-05-11 | 2018-07-24 | Abide Therapeutics Inc | methods of treating inflammation or neuropathic pain. |
CN107151220B (en) * | 2015-10-19 | 2021-07-20 | 中国医学科学院药物研究所 | Phenol compound containing benzyloxy phenyl, preparation method and application thereof |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
CN110121343B (en) * | 2016-09-12 | 2023-11-03 | 整体健康 | Bicyclic compounds useful as GPR120 modulators |
US10800773B2 (en) | 2016-09-12 | 2020-10-13 | Integral Health, Inc. | Monocyclic compounds useful as GPR120 modulators |
EP3515897B1 (en) | 2016-09-19 | 2021-08-18 | H. Lundbeck A/S | Piperazine carbamates as modulators of magl and/or abhd6 and their use |
CA3036765A1 (en) * | 2016-09-26 | 2018-06-21 | Qingdao Primedicine Pharmaceutical Co., Ltd. | N-methyl-d-aspartate receptor allosteric modulators and methods for their use |
EP3305781A1 (en) * | 2016-10-07 | 2018-04-11 | Deutsches Krebsforschungszentrum | Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6) |
JOP20190105A1 (en) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
JOP20190106A1 (en) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
CN109700804B (en) * | 2017-03-01 | 2021-06-25 | 浙江大学 | Tetrahydrocarbazole structure type androgen receptor antagonist and application thereof |
MX2019011867A (en) | 2017-04-03 | 2020-01-09 | Coherus Biosciences Inc | Pparî³ agonist for treatment of progressive supranuclear palsy. |
CN109305951A (en) * | 2017-07-26 | 2019-02-05 | 湖北固润科技股份有限公司 | Cumarin oxime ester compound and its preparation and application |
CN110283119A (en) * | 2018-04-20 | 2019-09-27 | 长沙理工大学 | A method of synthesizing complete carbon-based substituted pyridine derivative |
AU2019271123A1 (en) | 2018-05-15 | 2020-11-26 | H. Lundbeck A/S. | MAGL inhibitors |
CN110613717A (en) * | 2019-05-17 | 2019-12-27 | 中国医学科学院医药生物技术研究所 | Medicine for reducing blood fat |
CN110156708B (en) * | 2019-05-21 | 2022-08-09 | 中国药科大学 | Substituted heterocyclic compound containing acylhydrazone skeleton and preparation method and application thereof |
US11578073B2 (en) | 2019-06-20 | 2023-02-14 | Southern Research Institute | Xanthine analogs as potent anti-West Nile viral agents |
CN111362894B (en) * | 2020-03-12 | 2023-05-12 | 澳门科技大学 | Synthetic method of NHTD |
JP2023523219A (en) | 2020-04-21 | 2023-06-02 | ハー・ルンドベック・アクチエゼルスカベット | Synthesis of monoacylglycerol lipase inhibitors |
EP4164635A1 (en) * | 2020-06-16 | 2023-04-19 | President and Fellows of Harvard College | Compounds and methods for blocking apoptosis and inducing autophagy |
CN115475171A (en) * | 2021-06-16 | 2022-12-16 | 中国医学科学院医药生物技术研究所 | Compound with anti-coronavirus activity and application thereof |
CN115304600B (en) * | 2022-09-29 | 2023-01-13 | 北京鑫开元医药科技有限公司 | mTOR inhibitor, preparation method and application |
CN116041349B (en) * | 2022-12-27 | 2023-10-20 | 吉斯凯(苏州)制药有限公司 | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3121043A (en) * | 1960-05-11 | 1964-02-11 | Scient Associates Inc | Sustained release pharmaceutical preparation and methods for making same |
US4053614A (en) * | 1972-03-06 | 1977-10-11 | Bayer Aktiengesellschaft | 1,2-pentamethylene-1,4-dihydropyridine derivatives |
CA1053244A (en) * | 1973-04-17 | 1979-04-24 | Ciba-Geigy Ag | Imides |
US3975531A (en) * | 1973-10-02 | 1976-08-17 | A. H. Robins Company, Incorporated | 4-(5- And 7-)benzoylindolin-2-ones and pharmaceutical uses thereof |
JPS545996A (en) * | 1977-06-15 | 1979-01-17 | Yamanouchi Pharmaceut Co Ltd | Heterocyclic compounds and process for their preparation |
US4761424A (en) * | 1985-10-01 | 1988-08-02 | Warner-Lambert Company | Enolamides, pharmaceutical compositions and methods for treating inflammation |
LU86345A1 (en) * | 1986-03-06 | 1987-11-11 | Oreal | NOVEL BENZOFURAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND DRUG AND COSMETIC COMPOSITIONS CONTAINING THEM |
GB8814458D0 (en) * | 1988-06-17 | 1988-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
US5229401A (en) * | 1991-09-23 | 1993-07-20 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino benzo[b]thiophene compounds |
FR2694004B1 (en) * | 1992-07-21 | 1994-08-26 | Adir | News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them. |
EP2341045A1 (en) * | 1994-04-01 | 2011-07-06 | Eli Lilly and Company | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor |
JPH08157363A (en) * | 1994-12-02 | 1996-06-18 | Japan Energy Corp | Carcinostatic agent |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
JP2000505063A (en) * | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Azetidinone compounds for the treatment of atherosclerosis |
PT941221E (en) * | 1996-11-20 | 2003-07-31 | Altana Pharma Ag | SUBSTITUTED DIHYDROBENZOFURANES AS PHOSPHODIESTERASE INHIBITORS (PDE) |
JP3205899B2 (en) * | 1997-07-18 | 2001-09-04 | 株式会社浅井ゲルマニウム研究所 | Diagnostic reagent for complications associated with diabetes or renal failure |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US6689768B2 (en) * | 1998-04-15 | 2004-02-10 | Jenapharm Gmbh & Co. Kg | Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy |
FR2783169B1 (en) * | 1998-09-15 | 2001-11-02 | Sederma Sa | COSMETIC OR DERMOPHARMACEUTICAL USE OF PEPTIDES FOR HEALING AND FOR IMPROVING THE SKIN APPEARANCE DURING NATURAL OR ACCELERATED AGING (HELIODERMIA, POLLUTION) |
US20030153560A1 (en) * | 1999-04-23 | 2003-08-14 | Salituro Francesco G. | Inhibitors of c-Jun N-terminal kinases (JNK) |
US6528489B1 (en) * | 1999-09-23 | 2003-03-04 | Ergon Pharmaceuticals Llc | Mycotoxin derivatives as antimitotic agents |
WO2001036426A1 (en) * | 1999-11-19 | 2001-05-25 | Washington University | Pyridinones to treat and prevent bacterial infections |
US20030092635A1 (en) * | 1999-12-08 | 2003-05-15 | Aberg A K Gunnar | Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease |
EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
DE10025464A1 (en) * | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Combined use of enzyme inhibitors for the therapy of autoimmune diseases, in transplants and tumor diseases, as well as combinations of pharmaceutical preparations comprising enzyme inhibitors |
DE10026998A1 (en) * | 2000-05-31 | 2001-12-13 | Fresenius Kabi De Gmbh | Process for the preparation of a cosmetic composition comprising human serum albumin obtained from transgenic non-human mammals |
DE10100053A1 (en) * | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Use of enzyme inhibitors of dipeptidyl peptidase IV and aminopeptidase N and pharmaceutical preparations therefrom for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative processes and diseases |
JP2004520330A (en) * | 2001-01-02 | 2004-07-08 | インスティテュート ヒューア メディツィンテクノロギー マグデブルク ゲーエムベーハー イーエムテーエム | Treatment and prevention of arteriosclerosis, treatment and prevention of allergic reactions of the type Gel-Coombs type I, and treatment of skin diseases with follicular and epidermal hyperkeratosis and accelerated proliferation of keratinocytes Of enzyme inhibitor and its drug compound for drug and prevention |
CZ301487B6 (en) * | 2001-02-24 | 2010-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, process of their preparation and use as a medicament |
GB0125446D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
EP1469873A4 (en) * | 2001-11-26 | 2007-10-03 | Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
ATE409466T1 (en) * | 2002-01-11 | 2008-10-15 | Novo Nordisk As | METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION |
MXPA04007743A (en) * | 2002-02-13 | 2004-10-15 | Hoffmann La Roche | Novel pyridine- and quinoline-derivatives. |
BR0307665A (en) * | 2002-02-13 | 2005-01-04 | Hoffmann La Roche | Compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases associated with dpp iv and use of the compounds |
DE10211555A1 (en) * | 2002-03-15 | 2003-10-02 | Imtm Inst Fuer Medizintechnolo | Use of the inhibitors of enzymes with activities of the aminopeptidase N and / or the dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of dermatological diseases with sebocytic hyperproliferation and changed differentiation states |
DE10230381A1 (en) * | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them |
DE10238477A1 (en) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New purine derivatives, their production and their use as medicines |
DE10238470A1 (en) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New xanthine derivatives, their production and their use as medicines |
DE10251927A1 (en) * | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity |
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10337074A1 (en) * | 2003-08-12 | 2005-03-17 | Keyneurotek Ag | Use of the inhibitors of enzymes with activities of aminopeptidase N and / or dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of chronic neurodegenerative diseases |
DE10348023A1 (en) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | New alanyl aminopeptidase inhibitors for the functional manipulation of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
DE10348044A1 (en) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Dual alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
-
2003
- 2003-10-15 DE DE10348022A patent/DE10348022A1/en not_active Withdrawn
-
2004
- 2004-10-15 AU AU2004281959A patent/AU2004281959B9/en not_active Ceased
- 2004-10-15 US US10/575,883 patent/US20070037785A1/en not_active Abandoned
- 2004-10-15 CN CNA2004800348156A patent/CN1889960A/en active Pending
- 2004-10-15 CA CA002542807A patent/CA2542807A1/en not_active Abandoned
- 2004-10-15 JP JP2006534708A patent/JP2008500270A/en active Pending
- 2004-10-15 WO PCT/EP2004/011645 patent/WO2005037779A2/en active Application Filing
- 2004-10-15 EP EP04790487A patent/EP1675594A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2005037779A2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680150B2 (en) | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
Also Published As
Publication number | Publication date |
---|---|
US20070037785A1 (en) | 2007-02-15 |
DE10348022A1 (en) | 2005-05-25 |
AU2004281959A1 (en) | 2005-04-28 |
WO2005037779A3 (en) | 2005-07-07 |
CN1889960A (en) | 2007-01-03 |
WO2005037779A2 (en) | 2005-04-28 |
JP2008500270A (en) | 2008-01-10 |
AU2004281959B2 (en) | 2009-07-23 |
CA2542807A1 (en) | 2005-04-28 |
AU2004281959B9 (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005037779A2 (en) | Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | |
EP1673082A2 (en) | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases | |
EP1673075A2 (en) | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | |
EP1082314B1 (en) | New dipeptidyl peptidase iv effectors | |
DE60122341T2 (en) | 9-SUBSTITUTED MINOCYCLINE COMPOUNDS | |
DE2904445C2 (en) | N 1 - (4-amino-6,7-dimethoxy-2-quinazolyl) -N 1 -methyl-N 2 - (2-tetrahydrofuroyl) -1,3-propanediamine, its preparation and its pharmaceutical use | |
EP1948627B1 (en) | Novel dual peptidase inhibitors as prodrugs for the therapy of inflammatory and other disorders | |
EP1259498A1 (en) | 8,8a-dihydro-indeno 1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents | |
WO2002016312A2 (en) | Novel compounds inhibiting factor xa activity | |
EP1060175B1 (en) | Tryptase inhibitors | |
DE102007039429A1 (en) | Method for activating regulatory T cells | |
DE69837564T2 (en) | AZAHETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF HAIR LOSS AND NEUROLOGICAL DISEASES | |
DE3619426A1 (en) | AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION | |
EP1373234B1 (en) | Urokinase inhibitors | |
EP1720549A1 (en) | Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency | |
DE2028880A1 (en) | N-phenyl carbamoyl derivs of 3-beta-phenyl isopropyl-synononimines - - as psycho and cns | |
CH516593A (en) | Alpha amino-benzyl penicillins - useful as oral antibiotics | |
WO2004024149A1 (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
DE4301739A1 (en) | Treatment of primary tumours and viral diseases | |
DE10116768A1 (en) | Hypoglycemic medicaments useful for treating type II diabetes contain new or known N-aroyl-N'-phenyl-urea derivatives which are glycogen phosphorylase a inhibitors | |
DE4036782A1 (en) | SUBSTITUTED ANILIDES | |
DE3040737A1 (en) | SALTS OF 5-FLUOR-2-METHYL-1 (P- (METHYLSULFINYL) -BENZYLIDEN) -INDEN-3-ACETIC ACID, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
DE10125567A1 (en) | New N-aroyl-N'-(carbamoyl-phenyl)-urea derivatives, are glycogen phosphorylase a inhibiting hypoglycemic agents, especially useful for treating type II diabetes | |
WO2005030767A1 (en) | Novel macrocycles for treating tumor diseases | |
DE4216941A1 (en) | Para-substituted benzylamines and therapeutic agents containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060331 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ANSORGE, SIEGFRIED Inventor name: BANK, UTE Inventor name: TAEGER, MICHAEL Inventor name: NORDHOFF, KARSTEN Inventor name: STRIGGOW, FRANK |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KEYNEUROTEK PHARMACEUTICALS AG Owner name: IMTM GMBH |
|
17Q | First examination report despatched |
Effective date: 20080602 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20101012 |